Výsledky vyhledávání - "N den Broeder"

Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients

Autor: B van Ruijven, Frank Hoentjen, Tessa E H Römkens, Jeroen M. Jansen, Rachel L. West, M E de Jong, Lisa J T Smits, N. Den Broeder, Maurice G. Russel

Publikováno v: Journal of Crohn's and Colitis, 14, 7, pp. 888-895
Journal of Crohn's and Colitis, 14, 888-895

Background and Aims There is paucity of data on safety and efficacy of anti-tumour necrosis factor [TNF] in elderly inflammatory bowel disease [IBD] patients. We aimed to compare the long-term treatment failure rates and safety of a first anti-TNF ag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a38bc7c367921353502898d293373a
https://doi.org/10.1093/ecco-jcc/jjaa012

Zobrazit plný text záznamu

Plný text ve formátu HTML

OP0261 TREAT-TO-TARGET DOSE REDUCTION AND WITHDRAWAL STRATEGY OF TNF INHIBITORS IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL

Autor: C. Michielsens, N. den Broeder, F. van den Hoogen, E. Mahler, S. Teerenstra, D. van der Heijde, L. M. Verhoef, A. den Broeder

Publikováno v: Annals of the Rheumatic Diseases. 81:172-173

BackgroundTumour Necrosis Factor inhibitors (TNFi) are effective in Psoriatic Arthritis (PsA) and axial SpondyloArthritis (axSpA), but are associated with a somewhat increased infection risk, patient burden, and high costs. Treat-to-target (T2T) tape

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5174b5e1144434999b3d077a0db5ad4
https://doi.org/10.1136/annrheumdis-2022-eular.1430

Zobrazit plný text záznamu

POS0269 RESULTS OF ONE YEAR OBSERVATIONAL EXTENSION OF THE BRIDGE-PMR STUDY, A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL WITH RITUXIMAB IN POLYMYALGIA RHEUMATICA

Autor: T. Bolhuis, D. Marsman, A. Den Broeder, N. Den Broeder, A. Van der Maas

Publikováno v: Annals of the Rheumatic Diseases. 81:377-378

BackgroundGlucocorticoids (GC) are the cornerstone of treatment in Polymyalgia rheumatica (PMR) [1]. However, they are associated with considerable toxicity and inefficacy in part of the patients. Rituximab (RTX) was effective for PMR in a 21-week ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1282ac6ffcce1b57b46b4063a6f7251d
https://doi.org/10.1136/annrheumdis-2022-eular.1797

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis

Autor: E Savelkoul, P Thomas, L Derikx, N Den Broeder, T Römkens, F Hoentjen

Publikováno v: Journal of Crohn's and Colitis. 16:i422-i423

Background Anti-Tumour necrosis factor agents are essential therapeutics in moderate-to-severe Ulcerative Colitis (UC). Annual loss of response (LOR) and dose escalation (DE) risk in UC patients have not been systematically evaluated. This study aime

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cdd7f72f8623504cc3b50a6b1987b3a
https://doi.org/10.1093/ecco-jcc/jjab232.567

Zobrazit plný text záznamu

P589 Total thiopurine exposure and impact on the development of keratinocyte carcinomas in Inflammatory Bowel Disease patients; a case control study

Autor: F M Jansen, S Lubeek, N den Broeder, E Savelkoul, C Marcus, F Hoentjen, W van Dop

Publikováno v: Journal of Crohn's and Colitis. 16:i525-i526

Background Keratinocyte skin cancer (KSC) including basal-cell carcinomas (BCC) and cutaneous squamous cell carcinomas (SCC), is the most prevalent cancer-type in the Netherlands with an increasing incidence and impact on morbidity. In addition to ul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c180d03115fb90fcdb104463e34a0fef
https://doi.org/10.1093/ecco-jcc/jjab232.715

Zobrazit plný text záznamu

Favourable tolerability and drug survival of tioguanine versus methotrexate after failure of conventional thiopurines in Crohn's disease

Autor: E H J Savelkoul, M H J Maas, A R Bourgonje, F Crouwel, V B C Biemans, N den Broeder, M G V M Russel, T E H Römkens, N K de Boer, G Dijkstra, F Hoentjen

Publikováno v: Savelkoul, E H J, Maas, M H J, Bourgonje, A R, Crouwel, F, Biemans, V B C, den Broeder, N, Russel, M G V M, Römkens, T E H, de Boer, N K, Dijkstra, G & Hoentjen, F 2022, ' Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease ', Journal of Crohn's & colitis, vol. 16, no. 9, pp. 1372-1379 . https://doi.org/10.1093/ecco-jcc/jjac044
Journal of Crohn's and Colitis, 16, 1372-1379
Journal of Crohn's and Colitis, 16(9). Oxford University Press
Journal of Crohn's & colitis, 16(9), 1372-1379. Elsevier
Journal of Crohn's and Colitis, 16, 9, pp. 1372-1379

Background and Aims Both methotrexate and tioguanine can be considered as treatment options in patients with Crohn’s disease after failure of conventional thiopurines. This study aimed to compare tolerability and drug survival of methotrexate and t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6344a2397e3b0875b3ca5bfe7b37bb52
https://research.rug.nl/en/publications/f55164fa-079e-4830-96de-0ef05580b51f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání